Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB drug Cimzia is “biological innovation”

UCB drug Cimzia is “biological innovation”

23rd April 2008

A new drug to treat patients suffering from moderate to severe forms of Crohn’s disease has been hailed as a “biological innovation” by the chief executive of UCB Group.

Cimzia (certolizumab pegol), which was developed by the firm as a monthly treatment for the disease, is the only PEGylated anti-tumour necrosis factor alpha antibody that has indicated the reduction of symptoms and signs of Crohn’s disease, according to UCB Group.

Recently approved by the US Food and Drug Administration, the drug will provide a new option for monthly treatment for patients suffering from the disease and will be available to doctors and patients this week, according to UCB chief executive Roch Doliveux.

During clinical trials involving more than 1,500 patients, Cimzia was found to achieve and sustain positive response in patients, enabling those in remission after initial dosing to maintain this status with no further increase in dose.

According to crohns.org.uk, the disease was first identified in isolated cases in Scotland in 1913. Other drugs currently being developed to treat the disease include Thalidomide, Tacrolimus, Mycophenolate mofetil and Etancercept.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.